Placental Transfer of Antidepressant Medications: Implications for Postnatal Adaptation Syndrome

Clinical Pharmacokinetics

Volumn 54, Issue 4, 2015, Pages 359-370

  Ewing, Grace ^a   Tatarchuk, Yekaterina ^a   Appleby, Dina ^a   Schwartz, Nadav ^b   Kim, Deborah ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADAPTATION SYNDROME; AMNION FLUID; CLINICAL DECISION MAKING; DRUG METABOLISM; DRUG TRANSPORT; EX VIVO STUDY; FETOMATERNAL TRANSFUSION; FUNCTIONAL ANATOMY; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; MATERNAL PLASMA; NONHUMAN; PERINATAL PERIOD; PLACENTAL TRANSFER; POSTNATAL ADAPTATION SYNDROME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN BINDING; PUERPERAL DEPRESSION; REVIEW; UMBILICAL CORD BLOOD; ANATOMY AND HISTOLOGY; ANIMAL; ANIMAL MODEL; BLOOD; FEMALE; METABOLISM; NEONATAL ABSTINENCE SYNDROME; NEWBORN; PLACENTA; PREGNANCY;

ANIMALS; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MODELS, ANIMAL; NEONATAL ABSTINENCE SYNDROME; PLACENTA; PREGNANCY;

EID: 84925535391     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0233-3     Document Type: Review

References (70)

1. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698–709.
2. O’Hara MW, Wisner KL. Perinatal mental illness: definition, description and aetiology. Best Pract Res Clin Obstet Gynaecol. 2014;28:3–12.
3. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–5.
4. Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 196:544.e1–5.
5. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62:863–70.
6. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160:993–6.
7. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127:94–114.
8. Forsberg L, Naver L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants—clinical monitoring using neonatal abstinence score. PLoS One. 2014;9:e111327.
9. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–83.
10. Ray S, Stowe ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014;28:71–83.
11. Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier. Expert Opin Drug Metab Toxicol. 2012;8:1263–75.
12. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol. 2006;2:51–69.
13. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487–514.
14. Wang JS, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev. 2007;39:723–46.
15. DeVane CL, Stowe ZN, Donovan JL, Newport DJ, Pennell PB, Ritchie JC, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20:54–9.
16. Bhuiyan M, Petropoulos S, Gibb W, Matthews SG. Sertraline alters multidrug resistance phosphoglycoprotein activity in the mouse placenta and fetal blood–brain barrier. Reprod Sci. 2012;19:407–15.
17. DeVane L, Goetzl LM, Ramamoorthy S. Exposing fetal drug exposure. Clin Pharmacol Ther. 2011;89:786–8.
18. Prouillac C, Lecoeur S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab Dispos. 2010;38:1623–35.
19. Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol. 1996;52:379–83.
20. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol. 1996;51:403–11.
21. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123:369–75.
22. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv Drug Deliv Rev. 1999;38:81–97.
23. Rytting E, Wang X, Vernikovskaya DI, Zhan Y, Bauer C, Abdel-Rahman SM, et al. Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). Drug Metab Dispos. 2014;42:1773–9.
24. Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GD, Ahmed MS, et al. Bupropion metabolism by human placenta. Biochem Pharmacol. 2010;79:1684–90.
25. Mattison D. Clinical pharmacology during pregnancy. San Diego: Academic Press; 2013.
26. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73:330–7.
27. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28.
28. DeVane CL, Simpkins JW. Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. Drug Metab Dispos. 1985;13:438–42.
29. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008;69:652–8.
30. Shea AK, Oberlander TF, Rurak D. Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors. Can J Psychiatry. 2012;57:523–9.
31. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 1997;55:235–43.
32. Jornil J, Jensen KG, Larsen F, Linnet K. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci. 2011;44:265–72.
33. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11:537–46.
34. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004;14:225–38.
35. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998;26:572–5.
36. Nielsen KK, Flinois JP, Beaune P, Brosen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996;277:1659–64.
37. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101–21.
38. Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther. 2011;90:67–76.
39. Houston ML. The development of the baboon (Papio sp.) placenta during the fetal period of gestation. Am J Anat. 1969;126:17–29.
40. DeVane CL, Boulton DW, Miller LF, Miller RL. Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol. 1999;2:17–23.
41. DeVane CL. Pharmacokinetic correlates of fetal drug exposure. NIDA Res Monogr. 1991;114:18–36.
42. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, Stowe ZN. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry. 2006;163:145–7.
43. Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry. 2000;48:1032–4.
44. Kim J, Riggs KW, Rurak DW. Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. Drug Metab Dispos. 2004;32:212–21.
45. Olivier JD, Valles A, van Heesch F, Afrasiab-Middelman A, Roelofs JJ, Jonkers M, et al. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl). 2011;217:419–32.
46. Pohland RC, Byrd TK, Hamilton M, Koons JR. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol. 1989;98:198–205.
47. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One. 2008;3:e2782.
48. Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul Toxicol Pharmacol. 2004;40:185–206.
49. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG. 2002;109:1003–8.
50. Mhanna MJ, Bennet JB 2nd, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics. 1997;100:158–9.
51. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721–2.
52. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184–91.
53. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol. 2004;7:329–34.
54. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother–infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry. 2011;72:994–1001.
55. Devane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(Suppl):38–45 (discussion 46–7).
56. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95–100.
57. Briggs GG, Ambrose PJ, Ilett KF, Hackett LP, Nageotte MP, Padilla G. Use of duloxetine in pregnancy and lactation. Ann Pharmacother. 2009;43:1898–902.
58. Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health. 2011;14:169–72.
59. Earhart AD, Patrikeeva S, Wang X, Abdelrahman DR, Hankins GD, Ahmed MS, et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med. 2010;23:409–16.
60. Douglas BH, Hume AS. Placental transfer of imipramine, a basic, lipid-soluble drug. Am J Obstet Gynecol. 1967;99:573–5.
61. Hume AS, Douglas BH. Placental transfer of desmethylimipramine. Am J Obstet Gynecol. 1968;101:915–7.
62. Heikkinen T, Ekblad U, Laine K. Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. Psychopharmacology (Berl). 2001;153:450–4.
63. Sjoqvist F, Bergfors PG, Borga O, Lind M, Ygge H. Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: evidence for drug metabolism. J Pediatr. 1972;80:496–500.
64. Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. Biol Psychiatry. 2006;59:287–90.
65. Hale T. Medication and mothers’ milk. Amarillo: Hale Publishing; 2010.
66. Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6:89–98.
67. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281–90.
68. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50:281–94.
69. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm. 1982;1:406–17.
70. Satoh T, Yamamoto S, Moroi K. The metabolism and placental transfer of isocarboxazid in pregnant rats. Jpn J Pharmacol. 1972;22(5):629–33.